Novel soluble myeloid cell leukemia sequence 1 (Mcl-1) inhibitor (E,E)-2-(benzylaminocarbonyl)-3-styrylacrylonitrile (4g) developed using a fragment-based approach | |
Zhang, Zhichao1; Song, Ting2,3; Li, Xiangqian1; Wu, Zhiyong1; Feng, Yingang4![]() | |
2013 | |
Source Publication | EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
![]() |
Volume | 59Issue:59Pages:141-149 |
Abstract | Based on a known nanomolar Bcl-2 homology domain 3 (BH3) mimetic 3-thiomorpholin-8-oxo-8Hacenaphtho[1,2-b] pyrrole-9-carbonitrile (S1,MW: 331), we applied a fragment-based approach to obtainBH3 mimetics with improved affinity and improved solubility in a watereethanol (9:1) cosolvent. After the deconstruction of 1 (S1), we obtained fragment cyanoacetamide (4), which was determined to be a ligand efficiency (LE) hot part. After a rational optimization through fragment evolution beginning with fragment 4, a smaller Mcl-1 inhibitor (E,E)-2-(benzylaminocarbonyl)-3-styrylacrylonitrile (4g, MW: 288) with a 6-fold increase in affinity compared to 1 was obtained, as predicted by our optimization curve and identified by Mcl-1 protein nuclear magnetic resonance (NMR). ; Based on a known nanomolar Bcl-2 homology domain 3 (BH3) mimetic 3-thiomorpholin-8-oxo-8H-acenaphtho[1,2-b] pyrrole-9-carbonitrile (SI, MW: 331), we applied a fragment-based approach to obtain BH3 mimetics with improved affinity and improved solubility in a water ethanol (9:1) cosolvent. After the deconstruction of 1 (S1), we obtained fragment cyanoacetamide (4), which was determined to be a ligand efficiency (LE) hot part. After a rational optimization through fragment evolution beginning with fragment 4, a smaller Mcl-1 inhibitor (E,E)-2-(benzylaminocarbonyl)-3-styrylacrylonitrile (4g, MW: 288) with a 6-fold increase in affinity compared to I was obtained, as predicted by our optimization curve and identified by Mcl-1 protein nuclear magnetic resonance (NMR). (C) 2012 Elsevier Masson SAS. All rights reserved. |
Subtype | Article |
Keyword | Mcl-1 Small Molecule Inhibitor Fragment-based Approach Anticancer |
Subject Area | 代谢物组学 |
WOS Headings | Science & Technology ; Life Sciences & Biomedicine |
DOI | 10.1016/j.ejmech.2012.10.050 |
WOS Keyword | SMALL-MOLECULE INHIBITORS ; LEAD DISCOVERY ; BCL-2 PROTEINS ; DRUG DISCOVERY ; SOLUBILITY ; DESIGN ; LIGAND ; DEGRADATION ; APOPTOSIS ; MIXTURES |
Indexed By | SCI ; IC |
Language | 英语 |
WOS Research Area | Pharmacology & Pharmacy |
WOS Subject | Chemistry, Medicinal |
WOS ID | WOS:000315554100016 |
Citation statistics | |
Document Type | 期刊论文 |
Identifier | http://ir.qibebt.ac.cn/handle/337004/1689 |
Collection | 代谢物组学研究组 |
Affiliation | 1.Dalian Univ Technol, Sch Chem, State Key Lab Fine Chem, Dalian 116012, Peoples R China 2.Peking Univ, State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China 3.Dalian Univ Technol, Sch Life Sci & Technol, Dalian 116024, Peoples R China 4.Chinese Acad Sci, Qingdao Inst BioEnergy & Bioproc Technol, Qingdao 266101, Peoples R China |
Recommended Citation GB/T 7714 | Zhang, Zhichao,Song, Ting,Li, Xiangqian,et al. Novel soluble myeloid cell leukemia sequence 1 (Mcl-1) inhibitor (E,E)-2-(benzylaminocarbonyl)-3-styrylacrylonitrile (4g) developed using a fragment-based approach[J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,2013,59(59):141-149. |
APA | Zhang, Zhichao.,Song, Ting.,Li, Xiangqian.,Wu, Zhiyong.,Feng, Yingang.,...&Chen, Hongbo.(2013).Novel soluble myeloid cell leukemia sequence 1 (Mcl-1) inhibitor (E,E)-2-(benzylaminocarbonyl)-3-styrylacrylonitrile (4g) developed using a fragment-based approach.EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,59(59),141-149. |
MLA | Zhang, Zhichao,et al."Novel soluble myeloid cell leukemia sequence 1 (Mcl-1) inhibitor (E,E)-2-(benzylaminocarbonyl)-3-styrylacrylonitrile (4g) developed using a fragment-based approach".EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 59.59(2013):141-149. |
Files in This Item: | Download All | |||||
File Name/Size | DocType | Version | Access | License | ||
Novel soluble myeloi(1330KB) | 开放获取 | CC BY-NC-SA | View Download |
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment